# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop nex...
Barclays analyst Carter Gould maintains AbbVie (NYSE:ABBV) with a Overweight and lowers the price target from $195 to $187.
BMO Capital analyst Evan David Seigerman maintains AbbVie (NYSE:ABBV) with a Outperform and lowers the price target from $19...
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and...